Simple Risk Assessment Predicts Post-PCI Ischemic Events medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Boston Scientific Initiates First Coronary Drug-Coated Balloon Study in the U.S.
AGENT IDE will evaluate the AGENT DCB as potential therapy for patients with in-stent restenosis, may offer alternative to repeated stenting or radiation therapy
May 20, 2021 Boston Scientific Corporation announced it has initiated the AGENT IDE trial for the AGENT Drug-Coated Balloon (DCB), the first clinical trial in the U.S. to evaluate the safety and effectiveness of a DCB in patients with coronary in-stent restenosis (ISR).
Coronary stenting, in which a stent is inserted into a coronary artery to restore blood flow to the heart, continues to show a substantial improvement in symptoms and quality of life for patients with coronary artery disease. However, in some patients, the stented section of the artery may become obstructed or narrowed by scar tissue, leading to a condition known as ISR. Approximately 10% of percutaneous coronary interventions (PCIs) address this issue and current treatme
Fluorescence-Guided Surgery Systems Market: Competitive openpr.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from openpr.com Daily Mail and Mail on Sunday newspapers.